{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:56:36Z","timestamp":1762253796874,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12325-021-01775-x","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T15:02:35Z","timestamp":1621868555000},"page":"3760-3770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15\u00a0mmHg and Under: ROCK U-15"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-1476","authenticated-orcid":false,"given":"Rei","family":"Sakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiroaki","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"issue":"10","key":"1775_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"issue":"9975","key":"1775_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295\u2013304.","journal-title":"Lancet"},{"key":"1775_CR3","unstructured":"The Japan Glaucoma Society. Glaucoma Practice Guidelines (4th edition). J Jpn Ophthalmol Soc. 2018;122(1):5\u201353."},{"issue":"12","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1177\/1060028014548569","volume":"48","author":"L Lin","year":"2014","unstructured":"Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014;48(12):1585\u201393.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"1775_CR5","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641\u20138.","journal-title":"Ophthalmology"},{"issue":"8","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ophtha.2018.12.029","volume":"126","author":"R Sakata","year":"2019","unstructured":"Sakata R, Yoshitomi T, Iwase A, et al. Factors associated with progression of Japanese open-angle glaucoma with lower normal intraocular pressure. Ophthalmology. 2019;126(8):1107\u201316.","journal-title":"Ophthalmology"},{"issue":"6","key":"1775_CR7","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-017-0552-5","volume":"34","author":"S Mizoue","year":"2017","unstructured":"Mizoue S, Nitta K, Shirakashi M, et al. Multicenter, randomized, investigator-masked study comparing brimonidine tartrate 0.1% and timolol maleate 0.5% as adjunctive therapies to prostaglandin analogues in normal-tension glaucoma. Adv Ther. 2017;34(6):1438\u201348.","journal-title":"Adv Ther"},{"issue":"9","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ophtha.2009.03.050","volume":"116","author":"TE Bournias","year":"2009","unstructured":"Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009;116(9):1719\u201324.","journal-title":"Ophthalmology"},{"issue":"7","key":"1775_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/archophthalmol.2010.131","volume":"128","author":"AP Tanna","year":"2010","unstructured":"Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch Ophthalmol. 2010;128(7):825\u201333.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/ICU.0000000000000134","volume":"26","author":"AP Tanna","year":"2015","unstructured":"Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol. 2015;26(2):116\u201320.","journal-title":"Curr Opin Ophthalmol"},{"issue":"15","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/14656566.2017.1378344","volume":"18","author":"T Inoue","year":"2017","unstructured":"Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opin Pharmacother. 2017;18(15):1669\u201373.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755\u201361.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s10384-018-0599-0","volume":"62","author":"K Inoue","year":"2018","unstructured":"Inoue K, Ishida K, Tomita G. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin\/timolol fixed combination therapy or adding ripasudil. Jpn J Ophthalmol. 2018;62(4):508\u201316.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-34.","journal-title":"Acta Ophthalmol"},{"key":"1775_CR15","unstructured":"Diggle P. Analysis of longitudinal data: Oxford Statistical Science. Oxford: Oxford University Press; 2013."},{"issue":"6","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.survophthal.2009.05.001","volume":"54","author":"MB Sultan","year":"2009","unstructured":"Sultan MB, Mansberger SL, Lee PP. Understanding the importance of IOP variables in glaucoma: a systematic review. Surv Ophthalmol. 2009;54(6):643\u201362.","journal-title":"Surv Ophthalmol"},{"key":"1775_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","volume":"176","author":"HS Barnebey","year":"2017","unstructured":"Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/bjo.2008.139329","volume":"92","author":"JA Cox","year":"2008","unstructured":"Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol. 2008;92(6):729\u201334.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1775_CR19","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00417-017-3727-5","volume":"255","author":"H Inazaki","year":"2017","unstructured":"Inazaki H, Kobayashi S, Anzai Y, et al. One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):2009\u201315.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"1775_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-016-0389-3","volume":"33","author":"S Sato","year":"2016","unstructured":"Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33(9):1628\u201334.","journal-title":"Adv Ther"},{"issue":"6","key":"1775_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40261-017-0509-0","volume":"37","author":"R Matsumura","year":"2017","unstructured":"Matsumura R, Inoue T, Matsumura A, Tanihara H. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Investig. 2017;37(6):535\u20139.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1775_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00417-018-3933-9","volume":"256","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Katsuyama A, Matsumiya W, Nakamura M. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):809\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1775_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s10384-018-0635-0","volume":"63","author":"T Komizo","year":"2019","unstructured":"Komizo T, Ono T, Yagi A, Miyata K, Aihara M. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma. Jpn J Ophthalmol. 2019;63(1):40\u20135.","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1775_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","volume":"28","author":"H Saito","year":"2019","unstructured":"Saito H, Kagami S, Mishima K, Mataki N, Fukushima A, Araie M. Long-term side effects including blepharitis leading to discontinuation of ripasudil. J Glaucoma. 2019;28(4):289\u201393.","journal-title":"J Glaucoma"},{"issue":"10","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ophtha.2015.06.039","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015;122(10):2010\u201321.","journal-title":"Ophthalmology"},{"issue":"4","key":"1775_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/fampra\/cmu031","volume":"31","author":"O Cohen Castel","year":"2014","unstructured":"Cohen Castel O, Keinan-Boker L, Geyer O, Milman U, Karkabi K. Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting. Fam Pract. 2014;31(4):453\u201361.","journal-title":"Fam Pract"},{"key":"1775_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the Phase 3 AYAME Study. Am J Ophthalmol. 2020;220:53\u201363.","journal-title":"Am J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01775-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T04:18:13Z","timestamp":1626236293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01775-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}